Inhibitory Effect of Tumor Suppressor p53 on Proinflammatory Chemokine Expression in Ovarian Cancer Cells by Reducing Proteasomal Degradation of IκB

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Son, Deok Soo ^a   Kabir, Syder M ^a   Dong, Yuan Lin ^a   Lee, Eunsook ^a   Adunyah, Samuel E ^a  

^a MEHARRY MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CXCL1 CHEMOKINE; CXCL2 CHEMOKINE; CXCL3 CHEMOKINE; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; PROTEIN MDM2; PROTEIN P53; TUMOR NECROSIS FACTOR ALPHA; UBIQUITIN PROTEIN LIGASE E3;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE MUTATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; NULL CELL; OVARY CANCER; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; UBIQUITINATION; UNINDEXED SEQUENCE;

CHEMOKINES; FEMALE; HUMANS; I-KAPPA B KINASE; INFLAMMATION MEDIATORS; NF-KAPPA B; OVARIAN NEOPLASMS; PROMOTER REGIONS, GENETIC; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEOLYSIS; PROTO-ONCOGENE PROTEINS C-MDM2; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITINATION;

EID: 84871782497     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0051116     Document Type: Article

References (41)

1. Chobanian N, Dietrich CS, (2008) Ovarian cancer. Surg Clin North Am 88: 285-299.
2. Ness RB, Cottreau C, (1999) Possible role of ovarian epithelial inflammation in ovarian cancer. J Natl Cancer Inst 91: 1459-1467.
3. Fleming JS, Beaugie CR, Haviv I, Chenevix-Trench G, Tan OL, (2006) Incessant ovulation, inflammation and epithelial ovarian carcinogenesis: revisiting old hypotheses. Mol Cell Endocrinol 247: 4-21.
4. Lee Z, Swaby RF, Liang Y, Yu S, Liu S, et al. (2006) Lysophosphatidic acid is a major regulator of growth-regulated oncogene alpha in ovarian cancer. Cancer Res 66: 2740-2748.
5. Yang G, Rosen DG, Zhang Z, Bast RC Jr, Mills GB, et al. (2006) The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis. Proc Natl Acad Sci USA 103: 16472-16477.
6. Ivarsson K, Runesson E, Sundfeldt K, Haeger M, Hedin L, et al. (1998) The chemotactic cytokine interleukin-8-a cyst fluid marker for malignant epithelial ovarian cancer? Gynecol Oncol 71: 420-423.
7. Ivarsson K, Ekerydh A, Fyhr IM, Janson PO, Brännström M, (2000) Upregulation of interleukin-8 and polarized epithelial expression of interleukin-8 receptor A in ovarian carcinomas. Acta Obstet Gynecol Scand 79: 777-784.
8. Schutyser E, Struyf S, Proost P, Opdenakker G, Laureys G, et al. (2002) Identification of biologically active chemokine isoforms from ascitic fluid and elevated levels of CCL18/pulmonary and activation-regulated chemokine in ovarian carcinoma. J Biol Chem 277: 24584-24593.
9. Duan Z, Feller AJ, Penson RT, Chabner BA, Seiden MV, (1999) Discovery of differentially expressed genes associated with paclitaxel resistance using cDNA array technology: analysis of IL-6, IL-8, and monocyte chemotactic protein 1 in the paclitaxel-resistant phenotype. Clin Cancer Res 5: 3445-3453.
10. Son DS, Parl AK, Rice VM, Khabele D, (2007) Keratinocyte chemoattractant (KC)/human growth-regulated oncogene (GRO) chemokines and pro-inflammatory chemokine networks in mouse and human ovarian epithelial cancer cells. Cancer Biol Ther 6: 1302-1312.
11. Landen CN Jr, Birrer MJ, Sood AK, (2008) Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol 26: 995-1005.
12. Gu L, Findley HW, Zhou M, (2002) MDM2 induces NF-κB/p65 expression transcriptionally through Sp1-binding sites: a novel, p53-independent role of MDM2 in doxorubicin resistance in acute lymphoblastic leukemia. Blood 99: 3367-3375.
13. Kawauchi K, Araki K, Tobiume K, Tanaka N, (2008) Activated p53 induces NF-κB DNA binding but suppresses its transcriptional activation. Biochem Biophys Res Commun 372: 137-141.
14. Kawauchi K, Araki K, Tobiume K, Tanaka N, (2009) Loss of p53 enhances catalytic activity of IKKβ through O-linked beta-N-acetyl glucosamine modification. Proc Natl Acad Sci USA 106: 3431-3436.
15. Ravi R, Mookerjee B, van Hensbergen Y, Bedi GC, Giordano A, et al. (1998) p53-mediated repression of nuclear factor-κB RelA via the transcriptional integrator p300. Cancer Res 58: 4531-4536.
16. Webster GA, Perkins ND, (1999) Transcriptional cross talk between NF-κB and p53. Mol Cell Biol 19: 3485-3495.
17. Ikeda A, Sun X, Li Y, Zhang Y, Eckner R, et al. (2000) p300/CBP-dependent and-independent transcriptional interference between NF-κB RelA and p53. Biochem Biophys Res Commun 272: 375-379.
18. Bohuslav J, Chen LF, Kwon H, Mu Y, Greene WC, (2004) p53 induces NF-κB activation by an IκB kinase-independent mechanism involving phosphorylation of p65 by ribosomal S6 kinase 1. J Biol Chem 279: 26115-26125.
19. Schneider G, Henrich A, Greiner G, Wolf V, Lovas A, et al. (2010) Cross talk between stimulated NF-κB and the tumor suppressor p53. Oncogene 29: 2795-2806.
20. Suzuki K, Matsubara H, (2011) Recent advances in p53 research and cancer treatment. J Biomed Biotechnol 2011: 978312.
21. Khabele D, Son DS, Parl AK, Goldberg GL, Augenlicht LH, et al. (2007) Drug-induced inactivation or gene silencing of class I histone deacetylases suppresses ovarian cancer cell growth: implications for therapy. Cancer Biol Ther 6: 795-801.
22. Wilson AJ, Holson E, Wagner F, Zhang YL, Fass DM, et al. (2011) The DNA damage mark pH2AX differentiates the cytotoxic effects of small molecule HDAC inhibitors in ovarian cancer cells. Cancer Biol Ther 12: 484-493.
23. Roby KF, Taylor CC, Sweetwood JP, Cheng Y, Pace JL, et al. (2000) Development of a syngeneic mouse model for events related to ovarian cancer. Carcinogenesis 21: 585-591.
24. Moradi MM, Carson LF, Weinberg B, Haney AF, Twiggs LB, et al. (1993) Serum and ascitic fluid levels of interleukin-1, interleukin-6, and tumor necrosis factor-α in patients with ovarian epithelial cancer. Cancer 72: 2433-2440.
25. Yaginuma Y, Westphal H, (1992) Abnormal structure and expression of the p53 gene in human ovarian carcinoma cell lines. Cancer Res 52: 4196-4199.
26. Jin X, Burke W, Rothman K, Lin J, (2002) Resistance to p53-mediated growth suppression in human ovarian cancer cells retain endogenous wild-type p53. Anticancer Res 22: 659-664.
27. Dreyfus DH, Nagasawa M, Gelfand EW, Ghoda LY, (2005) Modulation of p53 activity by IκBα: evidence suggesting a common phylogeny between NF-κB and p53 transcription factors. BMC Immunol 6: 12.
28. Zhou M, Gu L, Zhu N, Woods WG, Findley HW, (2003) Transfection of a dominant-negative mutant NF-κB inhibitor (IκBm) represses p53-dependent apoptosis in acute lymphoblastic leukemia cells: interaction of IκBm and p53. Oncogene 22: 8137-8144.
29. Van Maerken T, Ferdinande L, Taildeman J, Lambertz I, Yigit N, et al. (2009) Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53. J Natl Cancer Inst 101: 1562-1574.
30. Endo S, Yamato K, Hirai S, Moriwaki T, Fukuda K, et al. (2011) Potent in vitro and in vivo antitumor effects of MDM2 inhibitor nutlin-3 in gastric cancer cells. Cancer Sci 102: 605-613.
31. Ogawa H, Iimura M, Eckmann L, Kagnoff MF, (2004) Regulated production of the chemokine CCL28 in human colon epithelium. Am J Physiol Gastrointest Liver Physiol 287: G1062-G1069.
32. Kagami S, Saeki H, Komine M, Kakinuma T, Nakamura K, et al. (2006) CCL28 production in HaCaT cells was mediated by different signal pathways from CCL27. Exp Dermatol 15: 95-100.
33. Gu L, Zhu N, Findley HW, Woods WG, Zhou M, (2004) Identification and characterization of the IKKα promoter: positive and negative regulation by ETS-1 and p53, respectively. J Biol Chem 279: 52141-52149.
34. Salminen A, Kaarniranta K, (2010) Glycolysis links p53 function with NF-κB signaling: impact on cancer and aging process. J Cell Physiol 224: 1-6.
35. Huang WC, Ju TK, Hung MC, Chen CC, (2007) Phosphorylation of CBP by IKKβ promotes cell growth by switching the binding preference of CBP from p53 to NF-κB. Mol Cell 26: 75-87.
36. Tanaka K, Kawakami T, Tateishi K, Yashiroda H, Chiba T, (2001) Control of IκB proteolysis by the ubiquitin-proteasome pathway. Biochimie 83: 351-356.
37. Hwang IY, Baguley BC, Ching LM, Gilchrist CA, (2010) The ubiquitin-proteasome system is inhibited by p53 protein expression in human ovarian cancer cells. Cancer Lett 294: 82-90.
38. Marine JC, Lozano G, (2010) Mdm2-mediated ubiquitylation: p53 and beyond. Cell Death Differ 17: 93-102.
39. Wade M, Wang YV, Wahl GM, (2010) The p53 orchestra: Mdm2 and Mdmx set the tone. Trends Cell Biol 20: 299-309.
40. Liu G, Park YJ, Tsuruta Y, Lorne E, Abraham E, (2009) p53 attenuates lipopolysaccharide-induced NF-κB activation and acute lung injury. J Immunol 182: 5063-5071.
41. Rasmussen MK, Iversen L, Johansen C, Finnemann J, Olsen LS, et al. (2008) IL-8 and p53 are inversely regulated through JNK, p38 and NF-κB p65 in HepG2 cells during an inflammatory response. Inflamm Res 57: 329-339.